Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Dose Safety and Tolerability Study of E2609 in Healthy Japanese Subjects
jRCT2080223449Phase 1
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing E2609 50 mg once daily with Placebo once daily (2 arms).
02
Drugs
elenbecestat
Beyond the preview
Go deeper on jRCT2080223449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223449.